<DOC>
	<DOCNO>NCT02801383</DOCNO>
	<brief_summary>ass efficacy safety recombinant human interferon α-2b gel ( Yallaferon® ) treatment patient cervical HPV-16 and/or HPV-18 infection ; analyze HPV type infection clinical negative conversion .</brief_summary>
	<brief_title>Recombinant Human Interferon a-2b Gel HPV-16 and/ HPV-18 Gynecological Infections</brief_title>
	<detailed_description>100 patient positive HPV-16 HPV-18 infection randomize interferon gel group control group ratio 1:1 ( 50 patient treatment group 50 patient control group ) . The patient treatment group receive 1g recombinant human α-2b interferon gel every day consecutive 6-10 course treatment , whereas treatment conduct control group .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Age 25 65 year age sex life female patient ; HPV DNA type test HPV16 and/ HPV18 positive 1 month . Patients cervical intraepithelial neoplasia Ⅱ / Ⅲ , cervical cancer ; Associated fungal vaginitis , trichomonas vaginitis , HIV positive patient ; Associated acute , severe bacterial viral infection ; Autoimmune diseases ; Within 3 month screen patient used corticosteroid , immunosuppressant antiviral drug ; Allergies allergy drug know ingredient ; History suffer CNS disease , epilepsy and/or psychological disorder ; Pregnant lactate woman ; The researcher consider appropriate clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>